Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders.
Evrensel, Alper, Ceylan, Mehmet Emin · Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2016 · DOI
Quick Summary
This review examines fecal microbiota transplantation (FMT)—a treatment where healthy gut bacteria from a donor are transferred to a patient—and its potential use in treating brain and mental health conditions. While FMT is already proven effective for certain gut infections and inflammatory bowel diseases, researchers are exploring whether it might help with conditions like ME/CFS, autism, and Parkinson's disease. Early results are promising, but much more research is needed to understand if it's safe and effective long-term.
Why It Matters
This review is relevant to ME/CFS because it identifies ME/CFS among conditions showing promising case report data for FMT and highlights the gut-brain axis as a potential mechanistic target. For ME/CFS patients and researchers exploring biomedical mechanisms, this review underscores growing interest in microbiota-based interventions and the need for rigorous clinical trials to test whether FMT could address proposed dysbiotic mechanisms in the disease.
Observed Findings
FMT has a documented 1700-year history as a treatment modality.
FMT is established and effective for gastrointestinal diseases including C. difficile infection, Crohn's disease, and ulcerative colitis.
Case reports describe potential effectiveness of FMT in autism, Parkinson's disease, multiple sclerosis, ME/CFS, and irritable bowel syndrome.
FMT is a technically simple, inexpensive, and reliable implementation method.
Long-term safety risks and standardized application protocols for FMT remain undefined.
Inferred Conclusions
The microbiota-gut-brain axis is a plausible mechanistic pathway relevant to neuropsychiatric disorder pathogenesis.
FMT warrants further investigation in neuropsychiatric conditions based on promising early case reports and emerging gut-brain axis research.
Despite technical and cost advantages, regulatory and protocol standardization are necessary before FMT can be clinically recommended for neuropsychiatric use.
Remaining Questions
What are the long-term safety profiles and adverse event rates for FMT, particularly in neuropsychiatric populations?
What standardized donor selection, preparation, and administration protocols should be established for neuropsychiatric applications?
What This Study Does Not Prove
This review does not establish efficacy of FMT for ME/CFS or any neuropsychiatric disorder—it only catalogs case reports and early-stage evidence. It does not demonstrate that dysbiosis causes ME/CFS symptoms, nor does it prove FMT would be safe or effective as a treatment. The review explicitly notes that long-term risks are unknown and standard protocols are not established, so conclusions about clinical utility cannot yet be drawn.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
Can rigorous randomized controlled trials demonstrate efficacy of FMT in ME/CFS and other neuropsychiatric disorders, and if so, in which patient subgroups?
What microbiota composition changes mediate any therapeutic benefit observed in neuropsychiatric conditions?